Therapy of short stature with growth hormone developments 10 years after the introduction of recombinant growth hormone
Developments 10 years after the introduction of
recombinant growth hormone
10 years after the introduction of recombinant growth
hormone (WH) into the therapy of small children, our experience is
increasingly shaped by the analysis of extensive
Growth hormone deficiency: These
show that the growth hormone deficiency with its various causes and
pathogenetic manifestations remains the most common indication for
WH. The problems remain in the timely and rational diagnosis and in
the optimization and individualization of the therapy to achieve
the growth goals from an economic point of view and at the same
time therapeutic safety. These problems can now be solved by WH
Further indications: It also shows
that the short stature in Ullrich-Turner syndrome and in renal
insufficiency, for which WH is approved, can be successfully
treated. In the case of a large number of other growth disorders,
there is the possibility of size improvement in individual cases.
In light of today's experience, an individual healing attempt can
be put on a rational basis.
Future prospects: In the future, the
broad potential of growth hormone will be exploited beyond the
indication of short stature.
Recombinant growth hormone (rGH) therapy in the
treatment of children with short stature was introduced 10 years
ago, and experience has shown that progress in implementing this
mode of therapy depends increasingly on analyses of large
pharmaco-epidemiological studies. These studies prove that the
diagnosis of growth hormone deficiency, whatever the cause or
pathogenetic form, is the most frequent indication for GH therapy.
The remaining problems are the timely and precise diagnosis, and
the best possible and individual therapy aiming at the projected
height and taking safety and costs into account. We are closer to
solving these problems today than ever before.
Apart from this, the use of GH in treating short
stature in Turner syndrome and renal insufficiency has led
tienda en llnea to its
acceptance as a suitable therapy for these patients. Height
improvement in a number of other growth disorders is, in certain
cases, also possible through GH therapy. In the light of current
experience, GH therapy can thus be attempted on a rational basis in
individual cases. This form of treatment clearly holds wider
possibilities and its implementation is likely to go beyond short
stature in the future.